Novel Botulinum Toxin Type A
OBI-858, a new clostridium botulinum toxin Type A preparation with expected uses in medicine and cosmetology, underwent toxicity studies and bulk clinical-use drug production and drug stability studies that were completed in 2015. The Company is currently working on the development of bacteria-free packing processes of the finished drug as well as dosage form research. In the future, the Company will qualify a cGMP manufacturer to handle production of finished drugs for a clinical studies. The Company is actively seeking a co-development partner to jointly development this drug.